1. Home
  2. CISS vs LGVN Comparison

CISS vs LGVN Comparison

Compare CISS & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo C3is Inc.

CISS

C3is Inc.

HOLD

Current Price

$1.29

Market Cap

1.7M

ML Signal

HOLD

Logo Longeveron Inc.

LGVN

Longeveron Inc.

HOLD

Current Price

$2.49

Market Cap

21.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CISS
LGVN
Founded
2022
2014
Country
Greece
United States
Employees
N/A
N/A
Industry
Marine Transportation
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7M
21.4M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
CISS
LGVN
Price
$1.29
$2.49
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$3.00
AVG Volume (30 Days)
403.8K
280.4K
Earning Date
05-19-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
50.76
EPS
N/A
N/A
Revenue
N/A
$709,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$10.81
P/E Ratio
$0.82
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.06
$0.48
52 Week High
$6.06
$7.60

Technical Indicators

Market Signals
Indicator
CISS
LGVN
Relative Strength Index (RSI) 49.22 36.32
Support Level $0.76 $0.61
Resistance Level $1.84 $7.30
Average True Range (ATR) 0.15 0.47
MACD -0.06 -0.52
Stochastic Oscillator 30.51 1.41

Price Performance

Historical Comparison
CISS
LGVN

About CISS C3is Inc.

C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including national and private industrial users, commodity producers, and traders. The company owns and operates a fleet of two dry bulk carriers that transport bulk commodities such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers.

About LGVN Longeveron Inc.

Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.

Share on Social Networks: